Form 4 for EWTX Edgewise Therapeutics, Inc.
Accepted 2023-05-03 00:00:00 ET · period of report 2023-05-01 · accession 0001562180-23-003918 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-03 | 2023-05-02 | EWTX | KOCH KEVIN | Pres, CEO, Dir | S - Sale+OE | $8.90 | -3,203 | 7,213 | -31% | -$28.5K |
| D | 2023-05-03 | 2023-05-01 | EWTX | KOCH KEVIN | Pres, CEO, Dir | M - OptEx | $0.00 | +10.4K | 10.4K | New | $0 |
| D | 2023-05-03 | 2023-05-01 | EWTX | KOCH KEVIN | Pres, CEO, Dir | M - OptEx | $0.00 | -10.4K | 20.8K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-02 | S | D | 3,203 | $8.90 | 7,213 | D | — | — | (F1) Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. (F2) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-05-01 | M | A | 10,416 | $0.00 | 10,416 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-05-01 | M | D | 10,416 | $0.00 | 20,834 | D | $0.00 · — to 2032-05-01 | 10,416 Common Stock | (F7) RSUs granted to the Reporting Person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. |